摘要前列腺癌的发病率近年呈现明显的上升趋势.18F-脱氧葡萄糖(FDG)是一种广谱的肿瘤显像剂,但在前列腺癌的应用上存在“盲区”,开发性能更加优良的前列腺显像剂有助于弥补上述不足.目前已有多种正电子显像剂可用于前列腺癌显像,但总体优势并不明显.最近新的68Ga-前列腺特异膜抗原(PSMA)显像剂在前列腺癌的临床应用中显示出更好的价值,现就其研究进展予以综述.

abstractsThe incidence of prostate cancer has shown an obvious upward trend in recent years.18F-fluorodeoxyglucose(FDG)is a broad-spectrum imaging agent for cancer,but there is a " blind zone" in the application of prostate cancer.Therefore,exploring prostate imaging agents with better performance can help to make up the deficiency.At present,there are a number of positron imaging agents for prostate cancer,but the overall advantage is not obvious.Recently,a new imaging agent,68Ga-prostate specific membrane antigen(PSMA),has been demonstrated its better value in clinical application of prostate cancer.This review summarizes the research progress of 68 Ga-PSMA,